Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients

作者：Gaye Hafez, Jolanta Małyszko, Aleksandra Golenia, Aleksandra Klimkowicz‐Mrowiec, Ana Carina Ferreira, Mustafa Arıcı, Annette N. Bruchfeld, Dorothea Nitsch, Ziad A. Massy, Marion Pépin, Giovambattista Capasso, Laila‐Yasmin Mani, Sophie Liabeuf, CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target), Giovambattista Capasso, Alexandre Andrade, Maie Bachmann, Inga Arūnė Bumblytė, Adrian Constantin Covic, Pilar Delgado, Nicole Endlich, Andreas Engvig, Denis P. Fouque, Casper F. M. Franssen, Sebastian Frische, Liliana Gârneaţă, Loreto Gesualdo, Konstantinos Giannakou, Dimitrios S. Goumenos, Ayşe Tuğba Kartal, Sophie Liabeuf, Laila‐Yasmin Mani, Hans-Peter Marti, Christopher Clemens Mayer, Rikke Nielsen, Vesna Pešić, Merita Rroji, Giorgos K. Sakkas, Goce B. Spasovski, Kate Stevens, Evgueniy Stefanov Vazelov, Davide Viggiano, Lefteris C. Zacharia, Ana Carina Ferreira, Jolanta Malyszko, Ewout Jasper Hoorn, Andreja Figurek, Robert John Unwin, Carsten Alexander Wagner, Christoph Wanner, Annette N. Bruchfeld, Marion Pépin, Andrzej Więcek, Dorothea Nitsch, Ivo Fridolin, Gaye Hafez, María José Soler Romeo, Michelangela Barbieri, Bojan Batinić, Laura Carrasco, Sol M. Carriazo, Ron T. Gansevoort, Gianvito Martino, Francesco U.S. Mattace-Raso, Ionuţ Nistor, Alberto Ortíz, Giuseppe Paolisso, Daiva Rastenytė, Gabriel Ştefan, Gioacchino Tedeschi, Ziad A. Massy, Boris T. Bikbov, Karlhans Endlich, Olivier Godefroy, Anastassia Kossioni, Justina Kurganaite, Norberto Perico, Giuseppe Remuzzi, Tomasz K. Grodzicki, Francesco Trepiccione, Carmine Zoccali, Mustafa Arıcı, Peter J. Blankestijn, Kai‐Uwe Eckardt, Danilo Fliser, Eugenio Gutiérrez Jiménez, Maximilian König, Ivan Rychlík, Michela Deleidi, György Reusz, Michele Farisco, Norberto Perico, Pedro Imenez Silva, Mickaël Bobot, Aleksandra Golenia, Alessandra Fortunata Perna, Alma Idrizi, Brian Bekker Hansen, Mariadelina Simeoni · 发表于：Clinical Kidney Journal · 年份：2023 · DOI：10.1093/ckj/sfad239 · 被引用次数：35 · 研究领域：Blood Pressure and Hypertension Studies、Pharmaceutical Practices and Patient Outcomes、Anesthesia and Sedative Agents

There is growing evidence that chronic kidney disease (CKD) is an independent risk factor for cognitive impairment, especially due to vascular damage, blood-brain barrier disruption and uremic toxins. Given the presence of multiple comorbidities, the medication regimen of CKD patients often becomes very complex. Several medications such as psychotropic agents, drugs with anticholinergic properties, GABAergic drugs, opioids, corticosteroids, antibiotics and others have been linked to negative effects on cognition. These drugs are frequently included in the treatment regimen of CKD patients. The first review of this series described how CKD could represent a risk factor for adverse drug reactions affecting the central nervous system. This second review will describe some of the most common medications associated with cognitive impairment (in the general population and in CKD) and describe their effects.